Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Asundexian in Hepatic Impairment
NCT05419635Phase 1Completed
- Sponsor
- Bayer
- Start
- Jun 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of asundexian in thromboembolism, Atrial fibrillation (AFib), acute myocardial infarction (AMI) and 1 more (3 arms), sponsored by Bayer. Primary endpoints: Area under the concentration vs. time curve from zero to infinity, Area under the concentration vs. time curve for unbound drug and 2 more. Started Jun 2022; status: completed.
02
Drugs
asundexian
03
Conditions
thromboembolismAtrial fibrillation (AFib)acute myocardial infarction (AMI)ischemic stroke
Beyond the preview
Go deeper on NCT05419635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05419635.